NASDAQ: RAPT

US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the ex-Greater China rights to Jiangxi Jemincare Group’s long-acting anti-IgE antibody, JYB1904, through a significant licensing agreement. The deal involves an upfront payment of USD 35 million and potential milestone payments of up to USD 672.5…